Connect with us

Public Companies

Ketamine is Leading the Psychedelic Revolution: Here’s How to Invest

The FDA approval of Johnson & Johnson’s Spravato®—an esketamine nasal spray for treatment-resistant depression—marked the start of the psychedelic…

Published

on

The FDA approval of Johnson & Johnson’s Spravato®—an esketamine nasal spray for treatment-resistant depression—marked the start of the psychedelic revolution. While ketamine was well-known as an anesthetic and party drug, the regulatory approval opened the door to treating the leading cause of disability worldwide—depression.

Ketamine alleviates the symptoms of depression in a matter of hours, compared to weeks for antidepressants. Rather than affecting monoamine neurotransmitters like antidepressants (e.g., serotonin or dopamine), it acts on glutamate, the most common chemical messenger in the brain, which plays an important role in the synaptic changes that underlie memory.

Let’s look at ketamine’s growing role as a treatment for mental health conditions and how to invest in the drug that’s leading the psychedelics revolution.

Ketamine Clinics on the Rise

Most physicians use intravenous ketamine in the ER or OR setting as an anesthetic, but there’s a growing demand for outpatient ketamine infusions for mood and pain disorders. Ketamine Startup reckons that there are more than 200 outpatient ketamine clinics in the United States and these figures continue to rise as consumer awareness grows.

Health insurance has been a key barrier. Until recently, insurance companies have refused to cover ketamine infusions due to the lack of clinical research. Since the approval of Spravato in 2019, these companies have become more and more willing to cover part of insurance claims for generic ketamine infusions targeting chronic pain and mental health.

The body of research supporting ketamine also continues to grow. In mid-2020, the FDA expanded Spravato’s approvals to include patients having suicidal thoughts or those that have recently attempted to take their own lives. Researchers found that more than 40% of suicidal patients that received four weeks of treatment had greatly reduced depressive symptoms.

The combination of rising consumer awareness, growing evidence of efficacy, and health insurance coverage paints a very bullish picture for the future of ketamine clinics and treatments. Given the high level of efficacy reported in clinical research, these treatment centers could provide frontline support for mental health disorders.

Investing in Ketamine’s Growth

Investors have many options to invest in ketamine’s growth potential. For example, many companies are developing FDA-approved ketamine therapies targeting a wide range of mental health conditions. Other companies are building a nationwide footprint of ketamine clinics that could eventually expand to include other psychedelic therapies, like psilocybin.

Ehave Inc.’s (OTC Pink: EHVVF) KetaDASH aims to become the glue connecting patients with ketamine clinics and therapies. Through its web and mobile app, patients can easily create a profile, check the availability of medical professionals, and schedule appointments. Patients and medical professionals can also use the platform to manage therapies over time.

KetaDASH’s easy-to-use dashboard. Source: KetaDASH

In addition to KetaDASH, the company partnered with Brain Scientific to leverage data and artificial intelligence to correlate biomarkers for the identification of chronic pain, depression, general anxiety, ADHD, schizophrenia, and other mental health conditions. The company aims to correlate ketamine treatment and patient improvements.

Click here to receive an investor presentation and corporate updates

All these efforts also tie into its overarching goal of aggregating health data and analyzing it with machine learning algorithms to diagnose mental health disorders to evaluate treatment options. The company recently announced a partnership with Health Wizz and BurstIQ to enhance privacy and streamline the collection and organization of medical records.

Looking Ahead

Ketamine is the first psychedelic therapy to go mainstream following the FDA approval of Spravato® for treatment-resistant depression and suicidal ideations. Investors can participate in ketamine’s upside potential in a variety of ways, but eHave Inc. (OTC Pink: EHVVF) is taking one of the most innovative approaches through its KetaDASH and wider data-driven strategy.

For more information, visit the company’s website or download their investor presentation.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Ketamine is Leading the Psychedelic Revolution: Here’s How to Invest appeared first on CannabisFN.

Read More

Trending